Some Homeopathic Products May Put You At Risk: FDA

Maryland:  Consumers may use various types of unapproved drugs, such as homeopathic products, to treat or relieve different diseases and conditions. These products are often marketed as natural alternatives to approved prescription and nonprescription products and are widely available in the marketplace. Homeopathic products, however, are marketed without FDA review and may not meet modern standards for safety, effectiveness, quality and labeling.

It is FDA’s public health mission to protect consumers from unsafe, ineffective and poor-quality drug products, which may cause significant and even irreparable harm.

Homeopathic products are made from a wide range of substances, including ingredients derived from plants, healthy or diseased animal or human sources, minerals and chemicals, including known poisons or toxins.

Some homeopathic products are indicated for treating conditions in infants and children, and are manufactured from ingredients such as nux vomica, belladonna (deadly nightshade), mercurius solubilis (mercury) and plumbum aceticum (lead). These ingredients pose potentially toxic effects.

For example, nux vomica contains strychnine, which is a highly toxic, well-studied poison that is used to kill rodents. Producing such a product without proper manufacturing controls may result in products that exceed the labeled dilution/strength of the ingredients, which, given what they are made from, could place consumers at significant risk.

Related Posts

  • Pharma
  • August 1, 2025
  • 34 views
Trump pressures 17 pharma CEOs to cut US drug prices

WASHINGTON, July 31 (Reuters) – President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas,…

  • Pharma
  • August 1, 2025
  • 16 views
Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25%…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Trump pressures 17 pharma CEOs to cut US drug prices

Trump pressures 17 pharma CEOs to cut US drug prices

Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

Karnataka issues order to merge Ayush drug dept with State FDA

Karnataka issues order to merge Ayush drug dept with State FDA

Orchid Pharma buyback rights to novel antibiotic; stock up 5%

Orchid Pharma buyback rights to novel antibiotic; stock up 5%